Virtual Library

Start Your Search

Alexander Dobrovic

Author of

  • +

    P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.16-11 - Monitoring of Early Stage Lung Cancer Using Liquid Biopsies. (ID 14376)

      16:45 - 18:00  |  Presenting Author(s): Alexander Dobrovic

      • Abstract


      This study aims to validate the use of chromosome rearrangements as tumour-specific biomarkers for the detection of circulating tumour DNA (ctDNA) to enable monitoring of cancer using digital PCR.We consider that rearrangements are the best source of robust disease markers that can be used for every lung cancer patient without a clear truncal mutation. The current high cost of the whole genome sequencing required for identification of chromosome rearrangements is offset by the low cost, high sensitivity and specificity of the subsequent assays.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Methods for ctDNA detection using chromosome rearrangements that leverage advances in next generation sequencing (NGS), bioinformatics and droplet digital PCR (ddPCR) have now been developed by our laboratory.

      4c3880bb027f159e801041b1021e88e8 Result

      We are using whole genome sequencing and bioinformatic analysis of lung tumour samples. The genomic sequence was aligned to the human reference genome (hg19). Rearrangements were identified using the GRIDSS algoriths. Large numebers of potential genomic rearrangements ithat could be used as a biomarker to detect ctDNA were identified in each tumour. These were used to design primers which were used to monitor the success of surgical resection and to detect early relapse.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Patients with early-stage primary tumours are the group in which appropriately timed therapeutic intervention is most likely to make a clinical difference. Our study assesses ctDNA in a large cohort of lung cancer patients with early-stage primary tumours that are being treated with the primary aim of cure. In addtion, whole genome sequencing also identifies genomic information such as rare functional rearrangements and mutational burden which can also be used in patient management.